Purple Biotech Ltd. - Understand $ppbt stock

$PPBT Market Cap: $52.74 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$18.76M

TTM

Current Assets

$11.40M

Q1 2024

Current Liabilities

$8.510M

Q1 2024

Current Ratio

133.98%

Q1 2024

Total Assets

$39.86M

Q1 2024

Total Liabilities

$8.843M

Q1 2024

Book Value

$31.02M

Q1 2024

Cash

$9.985M

Q1 2024

P/E

-2.811

Nov 29, 2024 EST

Free Cash Flow

-$18.94M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue		$0.00	$0.00	$0.00	$1.000M	$1.000M	$100.0K	$0.00
YoY Change				-100.0%	0.0%	900.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2022	2021	2020	2019	2018	2017	2016
Revenue	$0.00	$0.00	$0.00	$1.000M	$1.000M	$100.0K	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Selling, General & Admin	$5.237M	$6.283M	$5.864M	$5.723M	$5.157M	$4.498M	$5.529M	$3.003M
YoY Change	-16.65%	7.15%	2.46%	10.98%	14.65%	-18.65%	84.12%
% of Gross Profit
Research & Development	$17.03M	$16.32M	$11.83M	$7.238M	$2.674M	$5.268M	$4.640M	$4.180M
YoY Change	4.38%	37.99%	63.4%	170.68%	-49.24%	13.53%	11.0%
% of Gross Profit
Depreciation & Amortization	$197.0K	$201.0K	$231.0K	$235.0K	$178.0K	$7.000K	$4.000K	$2.000K	$1.000K
YoY Change	-1.99%	-12.99%	-1.7%	32.02%	2442.86%	75.0%	100.0%	100.0%
% of Gross Profit
Operating Expenses	$22.27M	$22.60M	$17.92M	$13.20M	$8.009M	$8.879M	$11.17M	$7.183M
YoY Change	-1.47%	26.12%	35.81%	64.76%	-9.8%	-20.53%	55.55%
Operating Profit
YoY Change

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2022	2021	2020	2019	2018	2017	2016
Interest Expense	$843.0K	$108.0K	-$15.46M	$1.479M	$2.718M	-$947.0K	-$4.942M
YoY Change	680.56%	-100.7%	-1145.44%	-45.58%	-387.01%	-80.84%
% of Operating Profit
Other Income/Expense, Net				$0.00	-$461.0K	$0.00	$0.00
YoY Change				-100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Pretax Income		-$21.76M	-$17.83M	-$28.70M	-$5.677M	-$5.569M	-$12.91M	-$12.13M
YoY Change		22.07%	-37.89%	405.57%	1.94%	-56.87%	6.5%
Income Tax		$0.00	$0.00	$0.00	$216.0K
% Of Pretax Income
Net Earnings	$19.98M	$21.76M	-$18.38M	-$28.00M	-$5.850M	-$5.200M	-$12.18M	-$12.13M
YoY Change	-8.19%	-218.36%	-34.34%	378.62%	12.5%	-57.3%	0.43%
Net Earnings / Revenue					-585.0%	-520.0%	-12177.0%
Basic Earnings Per Share
Diluted Earnings Per Share		-$1.20	-$1.046M	-$2.435M	-$302.1K	-$366.1K	-$1.288M	-$2.107M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Cash & Short-Term Investments	$15.41M	$32.11M	$47.20M	$57.81M	$6.395M	$6.684M	$7.435M	$14.66M	$10.56M
YoY Change	-52.01%	-31.96%	-18.35%	803.91%	-4.32%	-10.1%	-49.27%	38.82%
Cash & Equivalents	$14.49M	$15.03M	$10.89M	$11.25M	$4.385M	$5.163M	$3.947M	$6.758M	$10.56M
Short-Term Investments	$923.0K	$17.08M	$36.31M	$46.56M	$2.010M	$1.521M	$3.488M	$7.899M
Other Short-Term Assets	$376.0K	$1.143M	$1.273M	$977.0K	$414.0K	$1.087M	$548.0K	$241.0K	$246.0K
YoY Change	-67.1%	-10.21%	30.3%	135.99%	-61.91%	98.36%	127.39%	-2.03%
Inventory
Prepaid Expenses
Receivables			$0.00	$500.0K
Other Receivables			$0.00	$0.00
Total Short-Term Assets	$15.79M	$33.26M	$48.47M	$59.28M	$8.302M	$8.514M	$7.983M	$14.90M	$10.80M
YoY Change	-52.53%	-31.39%	-18.23%	614.07%	-2.49%	6.65%	-46.42%	37.89%
Property, Plant & Equipment	$470.0K	$682.0K	$896.0K	$968.0K	$244.0K	$37.00K	$28.00K	$16.00K	$8.000K
YoY Change	-31.09%	-23.88%	-7.44%	296.72%	559.46%	32.14%	75.0%	100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$187.0K	$3.071M
YoY Change		-100.0%	-93.91%
Other Assets			$160.0K	$3.071M
YoY Change			-94.79%
Total Long-Term Assets	$28.51M	$21.37M	$21.73M	$24.52M	$6.416M	$6.209M	$6.200M	$16.00K	$8.000K
YoY Change	33.46%	-1.65%	-11.4%	282.19%	3.33%	0.15%	38650.0%	100.0%
Total Assets	$44.30M	$54.62M	$70.20M	$83.80M	$14.72M	$14.72M	$14.18M	$14.91M	$10.81M
YoY Change
Accounts Payable	$4.205M	$2.132M	$1.491M	$1.241M	$1.281M	$1.847M	$1.548M	$515.0K	$353.0K
YoY Change	97.23%	42.99%	20.15%	-3.12%	-30.64%	19.32%	200.58%	45.89%
Accrued Expenses	$2.790M		$1.967M	$1.650M	$1.109M	$913.0K	$413.0K
YoY Change			19.21%	48.78%	21.47%	121.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$188.0K	$194.0K	$199.0K	$207.0K	$195.0K
YoY Change	-3.09%	-2.51%	-3.86%	6.15%
Total Short-Term Liabilities	$7.183M	$7.058M	$4.250M	$3.098M	$3.546M	$3.314M	$3.973M	$1.273M	$1.198M
YoY Change	1.77%	66.07%	37.19%	-12.63%	7.0%	-16.59%	212.1%	6.26%
Long-Term Debt	$163.0K	$321.0K	$550.0K	$688.0K	$28.00K	$0.00	$0.00	$0.00	$0.00
YoY Change	-49.22%	-41.64%	-20.06%	2357.14%
Other Long-Term Liabilities	$2.659M	$145.0K	$292.0K	$265.0K	$285.0K	$405.0K	$1.522M	$256.0K	$185.0K
YoY Change	1733.79%	-50.34%	10.19%	-7.02%	-29.63%	-73.39%	494.53%	38.38%
Total Long-Term Liabilities	$2.822M	$466.0K	$842.0K	$953.0K	$313.0K	$405.0K	$1.522M	$256.0K	$185.0K
YoY Change	505.58%	-44.66%	-11.65%	204.47%	-22.72%	-73.39%	494.53%	38.38%
Total Liabilities	$10.10M	$7.711M	$5.371M	$4.414M	$4.297M	$4.200M	$6.775M	$1.529M	$1.383M
YoY Change	30.92%	43.57%	21.68%	2.72%	2.31%	-38.01%	343.1%	10.56%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $52.743 Million

About PURPLE BIOTECH LTD.

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Industry: Pharmaceutical Preparations Peers: MediWound Ltd. Sol-Gel Technologies Ltd. TARO PHARMACEUTICAL INDUSTRIES LTD